Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328474 | 0.85 | GAA (0.57) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6328207 | 0.83 | GAA (0.53) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6324829 | 0.82 | GAA (0.56) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6323563 | 0.82 | TSHR (0.57) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6332462 | 0.82 | HDAC1 (0.50) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6332336 | 0.82 | GAA (0.53) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6326426 | 0.81 | KMT2A (0.54) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6334202 | 0.80 | HDAC1 (0.50) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6323802 | 0.80 | HPGD (0.52) | MAPTTSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL6328519 | 0.80 | TP53 (0.52) | MAPTTSHRHPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | MAPT 729/4885TSHR 4656/4885HPGD 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.